文献速递细菌感染、耐药与抗菌药物

乙胺嘧啶体外抗加德纳菌活性优于甲硝唑且不损伤乳酸杆菌

Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本研究评估抗疟药磺胺多辛/乙胺嘧啶及其组分对细菌性阴道病相关菌种的体外活性。乙胺嘧啶抑制所有加德纳菌株,MIC为0.125–4 mg/L,低于甲硝唑的2–128 mg/L,且在3/4菌株中抑制生物膜优于甲硝唑,但对其他BV相关菌和L. crispatus无活性。

要点

  • 乙胺嘧啶对加德纳菌MIC 0.125–4 mg/L,低于甲硝唑2–128 mg/L。
  • 乙胺嘧啶在3/4加德纳菌株中抑制生物膜和可培养细胞优于甲硝唑。
  • 磺胺多辛/乙胺嘧啶对5/8加德纳菌株MIC低于甲硝唑,对L. crispatus无活性。

核心结论

  • 乙胺嘧啶及磺胺多辛/乙胺嘧啶可能作为细菌性阴道病的替代或辅助治疗,需进一步临床试验。

研究设计与样本

  • 体外研究,测定磺胺多辛/乙胺嘧啶(20:1)、磺胺多辛、乙胺嘧啶、甲硝唑和克林霉素对BV相关菌种及L. crispatus的MIC和MBC,并评估加德纳菌生物膜。

主要发现

  • 磺胺多辛无效应;乙胺嘧啶抑制所有加德纳菌株,MIC 0.125–4 mg/L,低于甲硝唑MIC 2–128 mg/L。
  • 乙胺嘧啶在3/4加德纳菌株中抑制生物膜质量积累和减少可培养细胞优于甲硝唑。
  • 磺胺多辛/乙胺嘧啶对5/8加德纳菌株MIC低于甲硝唑。
  • 磺胺多辛、乙胺嘧啶及磺胺多辛/乙胺嘧啶对其他BV相关菌种和L. crispatus无活性。

临床怎么用

  • 乙胺嘧啶对加德纳菌的体外活性优于甲硝唑且不损伤L. crispatus,提示其可能作为BV替代或辅助治疗,但需临床试验验证。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bacterial vaginosis (BV) is associated with significant reproductive health risks and high recurrence rates after standard antibiotic treatment. Sulfadoxine/pyrimethamine, an antimalarial drug, demonstrated unexpected clearance of BV in clinical trials, suggesting potential antimicrobial effects. Drug repurposing, which leverages existing drugs for new therapeutic applications, offers a promising approach to address the challenges of antimicrobial resistance and high recurrence rates in BV. OBJECTIVE: To determine the in vitro activity of sulfadoxine/pyrimethamine and its components, sulfadoxine and pyrimethamine, on key species associated with BV. METHODS: Minimum inhibitory concentration (MIC) and minimum bactericidal concentration were determined for sulfadoxine/pyrimethamine (20:1 ratio), sulfadoxine, pyrimethamine, and standard-of-care antibiotics, metronidazole and clindamycin, against BV-associated species (Gardnerella spp., Fannyhessea vaginae, Prevotella bivia) and Lactobacillus crispatus (vaginal health marker). Gardnerella biofilms were also exposed to sulfadoxine/pyrimethamine, pyrimethamine, or metronidazole, and biofilm biomass and biofilm cells culturability were assessed. RESULTS: Sulfadoxine had no effect, while pyrimethamine inhibited all Gardnerella strains with MIC values ranging from 0.125 to 4 mg/L, lower than MICs observed for metronidazole (2-128 mg/L). Pyrimethamine also outperformed metronidazole in inhibiting biofilm mass accumulation and reducing biofilm culturable cells in 3/4 Gardnerella strains. Sulfadoxine/pyrimethamine presented lower MICs than metronidazole for 5/8 Gardnerella strains. Sulfadoxine, pyrimethamine, and sulfadoxine/pyrimethamine showed no activity against other BV-associated species or L. crispatus. CONCLUSIONS: These findings suggest that pyrimethamine (and sulfadoxine/pyrimethamine) could be promising alternative or adjuvant therapies for BV, warranting further clinical trials.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Rosca AS, Chaponda EB, Beckers T, et al. Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus. J Antimicrob Chemother. 2025. PMID: 40391646. doi:10.1093/jac/dkaf157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。